Literature DB >> 28296712

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.

Roberto A Leon-Ferre1, Lisa A Kottschade, Matthew S Block, Robert R McWilliams, Roxana S Dronca, Edward T Creagan, Jacob B Allred, Val J Lowe, Svetomir N Markovic.   

Abstract

The optimal surveillance for patients with resected high-risk melanoma is controversial. Select locoregional or oligometastatic recurrences can be cured with salvage resection. Data on the ability of PET/CT to detect such recurrences are sparse. We evaluated whether surveillance PET/CT in patients with resected stage III-IV melanoma led to detection of clinically occult recurrences amenable to curative-intent salvage treatment. We retrospectively identified 1429 melanoma patients who underwent PET/CT between January 2008 and October 2012 at Mayo Clinic (Rochester, Minnesota). A total of 1130 were excluded because of stage I-II, ocular or mucosal melanoma, incomplete resection, PET/CT not performed for surveillance or performed at a different institution, and records not available. A total of 299 patients were eligible. Overall, 162 (52%) patients developed recurrence [locoregional: 77 (48%), distant: 85 (52%)]. The first recurrence was clinically occult in 98 (60%) and clinically evident in 64 (40%). Clinically evident recurrences were more often superficial (skin, subcutaneous, or nodal) or in the brain, whereas clinically occult recurrences more often visceral. Overall, 90% of all recurrences were detected by 2.8 years. In all, 70% of patients with recurrence underwent curative-intent salvage treatment (locoregional: 94%, distant: 48%), with similar rates for clinically occult versus clinically evident recurrences (66 vs. 75%, P=0.240). Overall survival was superior among those who underwent curative-intent salvage treatment [5.9 vs. 1.2 years; hazard ratio=4.27, 95% confidence interval (CI)=2.68-6.80; P<0.001], despite 79% developing recurrence again. PET/CT had high sensitivity (88%, 95% CI=79.94-93.31%), specificity (90%, 95% CI=88.56-91.56%), and negative predictive value (99%, 95% CI=98.46-99.52%). However, the positive predictive value was only 37% (95% CI=31.32-43.68%). In patients with resected stage III-IV melanoma, surveillance PET/CT detected a large proportion of clinically occult recurrences amenable to curative-intent salvage treatment. Despite a high rate of second relapse, curative-intent salvage treatment was associated with superior overall survival. Even though PET/CT had high sensitivity, specificity, and negative predictive value, positive predictive value was poor, highlighting the need for histologic confirmation of PET/CT-detected abnormalities.

Entities:  

Mesh:

Year:  2017        PMID: 28296712     DOI: 10.1097/CMR.0000000000000344

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  8 in total

Review 1.  Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.

Authors:  Chadwick L Wright; Eric D Miller; Carlo Contreras; Michael V Knopp
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

Review 2.  Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus.

Authors:  Begoña Campos-Balea; Ovidio Fernández-Calvo; Roberto García-Figueiras; Carlos Neira; Carmen Peña-Penabad; Carmela Rodríguez-López; Rocío Vílchez-Simo; María Quindós-Varela
Journal:  Clin Transl Oncol       Date:  2022-03-28       Impact factor: 3.340

3.  Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).

Authors:  Kristy Kummerow Broman; Tasha Hughes; Lesly Dossett; James Sun; Dennis Kirichenko; Michael J Carr; Avinash Sharma; Edmund K Bartlett; Amanda A G Nijhuis; John F Thompson; Tina J Hieken; Lisa Kottschade; Jennifer Downs; David E Gyorki; Emma Stahlie; Alexander van Akkooi; David W Ollila; Jill Frank; Yun Song; Giorgos Karakousis; Marc Moncrieff; Jenny Nobes; John Vetto; Dale Han; Jeffrey M Farma; Jeremiah L Deneve; Martin D Fleming; Matthew C Perez; Michael C Lowe; Roger Olofsson Bagge; Jan Mattsson; Ann Y Lee; Russell S Berman; Harvey Chai; Hidde M Kroon; Juri Teras; Roland M Teras; Norma E Farrow; Georgia Beasley; Jane Yuet Ching Hui; Lukas Been; Schelto Kruijff; Youngchul Kim; Syeda Mahrukh Hussnain Naqvi; Amod A Sarnaik; Vernon K Sondak; Jonathan S Zager
Journal:  Cancer       Date:  2021-04-07       Impact factor: 6.921

4.  Continuing and new roles for surgery in the management of patients with stage IV melanoma.

Authors:  Erica B Friedman; John F Thompson
Journal:  Melanoma Manag       Date:  2018-04-09

5.  Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.

Authors:  Brian R Gastman; Jonathan S Zager; Jane L Messina; Robert W Cook; Kyle R Covington; Brooke Middlebrook; Pedram Gerami; Jeffrey D Wayne; Sancy Leachman; John T Vetto
Journal:  Head Neck       Date:  2019-01-29       Impact factor: 3.147

6.  Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.

Authors:  Eddy C Hsueh; James R DeBloom; Jonathan Lee; Jeffrey J Sussman; Kyle R Covington; Brooke Middlebrook; Clare Johnson; Robert W Cook; Craig L Slingluff; Kelly M McMasters
Journal:  J Hematol Oncol       Date:  2017-08-29       Impact factor: 17.388

Review 7.  Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges.

Authors:  Matthew David Howard
Journal:  Yale J Biol Med       Date:  2020-03-27

8.  Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol.

Authors:  Mbathio Dieng; Nikita Khanna; Mai Thi Hoang Nguyen; Robin Turner; Sarah J Lord; Alexander M Menzies; Jay Allen; Robyn Saw; Omgo E Nieweg; John Thompson; Rachael L Morton
Journal:  BMJ Open       Date:  2020-11-05       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.